Frequency of the Common MYH Mutations (G382D and Y165C) in MMR Mutation Positive and Negative HNPCC Patients.

Hered Cancer Clin Pract

Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle and the Hunter Medical Research Institute, Newcastle, New South Wales, Australia.

Published: May 2005

Recently mutations in the MYH gene have been associated with a milder form of adenomatous polyposis which is characterized by a variable level of colonic polyps ranging from a few to several hundred. In the context of HNPCC it is not unusual to identify patients with a smattering of polyps. The MYH gene product is involved in DNA repair and indeed the hMSH2/hMSH6 complex (both genes being essential elements of the DNA mismatch repair pathway) is required to stimulate MYH activity. We reasoned that because of the clinical similarity of a subset of HNPCC patients to those described with MYH mutations and the role of the hMSH2/hMSH6 complex in the activation of MYH protein that MYH mutations may account for a small proportion of HNPCC patients. In a study of 442 HNPCC patients we identified MYH mutations at the same frequency as that expected in the general population. Nevertheless, two HNPCC families were identified harbouring biallelic changes in MYH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837300PMC
http://dx.doi.org/10.1186/1897-4287-3-2-65DOI Listing

Publication Analysis

Top Keywords

myh mutations
16
hnpcc patients
16
myh
9
myh gene
8
hmsh2/hmsh6 complex
8
hnpcc
6
mutations
5
patients
5
frequency common
4
common myh
4

Similar Publications

May-Hegglin anomaly associated nephropathy: Case series.

SAGE Open Med Case Rep

November 2024

Division of Nephrology, Hypertension and Transplant Nephrology, University of California, Irvine, CA, USA.

May-Hegglin anomaly (MHA) is a rare autosomal dominant disease associated with a mutation in the MYH-9 gene. It is characterized by macrothrombocytopenia and neutrophils with abnormal cytoplasmic inclusions. Clinical features of this disease include hearing loss, early cataracts, and renal failure.

View Article and Find Full Text PDF

Non-muscle myosin (NMII) motor proteins have diverse developmental functions due to their roles in cell shape changes, cell migration, and cell adhesion. Zebrafish are an ideal vertebrate model system to study the NMII encoding myh genes and proteins due to high sequence homology, established gene editing tools, and rapid ex utero development. In humans, mutations in the NMII encoding MYH genes can lead to abnormal developmental processes and disease.

View Article and Find Full Text PDF

Human Genetics of Atrial Septal Defect.

Adv Exp Med Biol

June 2024

Institute of Medical Genetics, University Medicine Oldenburg, Oldenburg, Germany.

Article Synopsis
  • Atrial septal defects (ASD) can be categorized into isolated cases and syndromic cases, the latter presenting with additional extracardiac abnormalities like developmental delays.
  • Isolated or familial ASDs usually involve genetic changes in cardiac transcription factors and sarcomeric protein genes, while syndromic ASDs are linked to a wider variety of genetic alterations affecting pathways involved in heart development.
  • The chapter summarizes current findings in genetics related to ASD, detailing specific genetic alterations and common syndromes identified through genome-wide association studies (GWAS).
View Article and Find Full Text PDF

Certain genetic alterations and right-sided primary tumor location are associated with resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer (mCRC). The phase 3 PARADIGM trial (n = 802) demonstrated longer overall survival with first-line anti-EGFR (panitumumab) versus antivascular endothelial growth factor (bevacizumab) plus modified FOLFOX6 in patients with RAS wild-type mCRC with left-sided primary tumors. This prespecified exploratory biomarker analysis of PARADIGM (n = 733) evaluated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes, focusing on a broad panel of gene alterations associated with resistance to EGFR inhibition, including KRAS, NRAS, PTEN and extracellular domain EGFR mutations, HER2 and MET amplifications, and ALK, RET and NTRK1 fusions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!